論文・著書
2024年
WNT/β-catenin Signaling and CD8+ Tumor-infiltrating Lymphocytes in Tremelimumab Plus Durvalumab for Advanced Hepatocellular Carcinoma
Kuwano A, Tanaka K, Takahira J, Suzuki H, Ohishi Y, Motomura K
in vivo 38(6) : 2774-2781, 2024-11
脾摘後の切除不能肝細胞癌に対しデュルバルマブ・トレメリムマブ併用療法が奏効した1例
古賀勇太 、桒野哲史 、長澤滋裕 、田中紘介 、矢田雅佳 、増本陽秀 、本村健太
肝臓 65(8) : 391-396, 2024-08
Diagnostic features of autoimmune hepatitis in SARS-CoV-2-vaccinated vs. unvaccinated individuals
Kuwano A, Nagasawa S, Koga Y, Tanaka K, Yada M, Masumoto A, Motomura K
Experimental and therapeutic medicine 28(3) : 337, 2024-06
Similar Efficacy Between Atezolizumab Plus Bevacizumab Versus Hepatic Arterial Infusion Chemotherapy For Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Cohort Study
Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, Motomura K
In Vivo 38(4) : 1854-1858, 2024-06
Dynamics of the neutrophil-to-lymphocyte ratio during lenvatinib treatment for unresectable hepatocellular carcinoma
Kuwano A, Yada M, Koga Y, Tanaka K, Ohishi Y, Masumoto A, Motomura K
Oncology Letters 28(1) : 14442, 2024-05
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma in Patients With Child-Pugh class B
Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, Motomura K
Cancer diagnosis & prognosis 4(2) : 111-116, 2024-03
Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, Motomura K
Cancer diagnosis & prognosis 4(1) : 34-41, 2024-01
